Hepatic fibrosis, like many other forms of chronic injury, is a stressor of major and quite literal global scale. Liver cirrhosis severely impacts the patient’s quality of life. Cirrhotic patients endure chronic tiredness, build-up of bodily fluids, and an overall suppression of the immune system. As the organ is replaced by fibrous connective tissue, it collapses. The daily suffering and the lack of real treatment makes the search for real therapies more critical. Current treatments only slow the decline; they do not reverse the process. Several of the Regenerative Medicine Thailand projects are aimed at filling this very gap. UC-MSCs in particular offer a unique biotechnology targeting the cellular endpoint of the terminal patient’s organ decline which will serve to bridge the gap in the market.
The Pathological Mechanism
Injuries to liver cells driving Liver Cirrhosis may occur from toxins and viruses, or metabolic changes. With the activation of stellate cells, there is an increase in the deposition of collagen and other extracellular matrix components. The scarring further exacerbates inflammation and necrosis and increases portal hypertension. Eventually, the liver loses the ability to detoxify. With regard to reversing cyclical fibrosis, we lack standard therapies—making UC-MSCs a major focus for Regenerative Medicine Thailand—that deal specifically with targeting stellate cells and initiating matrix degradation.
Conventional Treatments Limitations
Treatments for Liver Cirrhosis are more palliative than curative. Treatments are primarily aimed at relieving symptoms of cirrhosis and do not alter the disease progression. These treatments include the use of diuretics for ascites, β blockers for portal hypertension, and lactulose for hepatic encephalopathy. There are antivirals that can be taken to halt the progression of the viral infection; however, they do not reverse hepatic fibrosis. The only truly curative and definitive treatment available is an organ transplant once the disease has reached the end state, yet, it involves monumental problems like: a longstanding and chronic lack of organ donors, lifelong requirement for immunosuppression, and extremely prohibitive costs. UC-MSCs and Regenerative Medicine Thailand therapies are desperately needed in this scenario and are better than current treatments. The lack of current treatments for reversing fibrotic tissues further shows the necessity for regenerative cell-based therapies for organ reconstruction.
The Biological Superiority of UC-MSCs
The incorporation of UC-MSCs into therapy for Liver Cirrhosis conditions can be a game-changer for Regenerative Medicine Thailand. The umbilical-cord derived mesenchymal stem cells have significant immunomodulatory effects that can reverse severe organ damage. These MSCs home to damaged tissue and organ sites of severe injury in a targeted manner. In the hepatic injured tissue, they release large quantities of trophic factors in the form of exosomes and repair damage and reverse fibrosis. These exosomes contain anti-fibrotic proteins and cause activated hepatic stellate cells to undergo apoptosis and stop the overproduction of collagen. Additionally, they create matrix metalloproteinases that degrade the stiff extracellular matrix, creating space for the development of new functional tissue. They also promote the endogenous proliferation of hepatocytes and the re-establishment of liver function. Compared to adult-derived tissue stem cells, umbilical cord-derived tissue stem cells have higher proliferation and lower immunogenicity, eliminating the need for stringent HLA matching. Their unique immunological and biological characteristics make them the preferred choice for organ regeneration.
Figure 1: comparing of conventional treatment and biological of UC-MSCs
Future Directions in Thailand
The combination of UC-MSCs cellular therapy is one of the fast growing areas of development in medicine, especially in Southeast Asia. Placing the Regenerative Medicine Thailand initiatives at the leading edge of this medical innovation presents numerous opportunities. The country has a well-established medical tourism industry, coupled with advanced research institutes focused on biotechnologies, and an increasing government interest in promoting research and clinical trials for permanent solutions to difficult to treat diseases such as Liver Cirrhosis. Researchers have begun to optimize conditions for expanding stem cell cultures in extremely clean environments to maximize their viability at the moment of use. The country’s diverse genetics offers a promising platform for fine-tuning various cellular dosages. Compared to the USA and other western countries, Thailand has a more appropriate and affordable platform for the intensive bioengineering work. Thailand will be the leader in this cellular technology, which will draw international investment to the country, and will provide life saving therapies to its citizens who previously had no other treatment options.
Comprehensive Conclusion
The shift from end stage hepatic failure with the provision of restorative cellular therapies breaks the burden of chronic disease. The advanced paracrine systems of UC-MSCs can now halt the destructive progression of Liver Cirrhosis. By disrupting the fibrotic bands and creating new hepatocytes, this technology has the potential to revolutionize the way we treat the condition. The challenges of organ transplantation will be avoided, since these cellular modulators are accessible and easy to use. The development of Regenerative Medicine Thailand shows commitment to making these therapies accessible to patients around the globe. Patients who face extreme and rapid decline no longer have to face a hopeless outcome. Stem cell technologies are guaranteed to create a new era in health care systems.